The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Molecular profiling and targeted combination strategies in pancreatic cancer
Zev Wainberg, MD, University of California, Los Angeles, CA, emphasizes the importance of sequencing every patient with pancreatic cancer to identify actionable subsets and develop targeted therapies. Dr Wainberg highlights the discovery of new subgroups, such as MTAP loss, which can be treated with PRMT5 inhibitors combined with KRAS inhibition, and notes that various combinations of therapies are being explored. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
